• 23 - Radiolegati

  • Oct 24 2024
  • Length: 4 mins
  • Podcast

23 - Radiolegati

Listen for free

View show details

  • Summary

  • La terapia con radioligandi permette di far pervenire radiazioni citotossiche direttamente al tumore e rappresenta un importante settore di sviluppo farmacologico. Al momento emergono nuovi dati soprattutto con il [¹⁷⁷Lu]Lu-PSMA-617 per il carcinoma prostatico e con il [¹⁷⁷Lu]Lu-DOTA-TATE per i tumori neuroendocrini, ma nuove formulazioni sono in arrivo.
    Con i due articoli segnalati (UpFrontPMSA e NETTER-2) i radioligandi sembrano uscire dal setting precedentemente studiato delle fasi avanzate e per tumori resistenti, per guadagnarsi l’attenzione nelle prima linee di trattamento.

    Bibliografia
    • Azad AA,, et al. Sequential [¹⁷⁷Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. Lancet Oncol 2024; 25: 1267-1276
    • Sing S, et al. [¹⁷⁷Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study . Lancet 2024; 403: 2807–2817
    Show More Show Less
Show More Show Less

What listeners say about 23 - Radiolegati

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.